QIAGEN and Clinical Genomics Partner on Liquid Biopsies to Monitor Patients for Recurrence of Colorectal Cancer

HILDEN, Germany, GERMANTOWN, Maryland and BRIDGEWATER, New Jersey, August 21, 2017 /PRNewswire/ --

QIAGEN (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) and Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced they have implemented the PAXgene^® Blood ccfDNA Tube* sample collection in Clinical Genomics' Colvera™ colorectal cancer ("CRC") recurrence assay. Colvera, an integrated liquid biopsy solution, is designed to enable easy and accurate monitoring for recurrence of colorectal cancer with a simple blood test collected in a physician's office.

"The Colvera test represents a unique opportunity for convenient, non-invasive monitoring of colorectal cancer patients by detecting methylated circulating tumor DNA that may indicate recurrence of a cancer. We are pleased to collaborate with Clinical Genomics in expanding the range of benefits made possible through liquid biopsies, which hold great promise for improving the lives of patients in cancer and other fields of medicine," said Thierry Bernard, Senior Vice President and Head of QIAGEN's Molecular Diagnostics Business Area.

"We are extremely pleased to use the highly automated QIAsymphony PAXgene Blood ccfDNA collection and sample processing workflow for collection and handling of Colvera samples. As a long-term commercial and research partner of QIAGEN, we have a great deal of confidence in this new solution," said Dr. Lawrence LaPointe, CEO of Clinical Genomics. "We are excited to roll out the PAXgene System as the front-end solution to allow physicians to provide Colvera testing to CRC patients as conveniently as possible. PAXgene allows a simple blood collection at the physician's office, with no on-site processing required, which is a great step forward from our alternative sample collection methods."

Click here for the full press release

http://corporate.qiagen.com/newsroom/press-releases/2017/2017-08-21-PAXgene-Colvera

Contacts: 
QIAGEN 
Investor Relations                     
John Gilardi 
+49-2103-291-1711        
e-mail:[email protected]

Public Relations
Dr. Thomas Theuringer
+49-2103- 291-1826
e-mail: [email protected] 

CLINICAL GENOMICS 
Media
Patty Jenkins        
+1-908-300-8673
e-mail:[email protected]
 

SOURCE QIAGEN N.V.